Open Fluoxetine Treatment of Mixed Anxiety Disorders in Children and Adolescents
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
An open-label pilot study examined fluoxetine treatment in 16 outpatients (9-18 years old) with mixed anxiety disorders. Following nonresponse to psychotherapy, fluoxetine monotherapy was started at 5 mg daily and was increased weekly by 5 or 10 mg daily for 6-9 weeks until improvement occurred or to a maximum of 40 mg (children under 12) or 80 mg (adolescents). Among patients on fluoxetine, severity of illness ratings were "much improved" (mean final Clinical Global Impression scale score 2.8 +/- 0.7). Clinical improvement occurred in 10 of 10 patients with current separation anxiety disorder, 8 of 10 with social phobia, 4 of 6 with specific phobia, 3 of 5 with panic disorder, and 1 of 7 with generalized anxiety disorder. Mean time to improvement was 5 weeks. Mean doses were 24 mg (0.7 mg/kg) for children and 40 mg (0.71 mg/kg) for adolescents. Side effects were transient and included drowsiness (31% of patients), sleep problems (19%), decreased appetite (13%), nausea (13%), abdominal pain (13%), and excitement (13%). No patient developed disinhibition, akathisia, or suicidality. These preliminary findings suggest fluoxetine effectiveness in separation anxiety disorder and social phobia. Youths with only one anxiety disorder appeared to respond to lower doses of fluoxetine than patients with multiple anxiety disorders (0.49 +/- 0.14 versus 0.80 +/- 0.28 mg/kg, p < 0.05).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.3.374 · Cited by 261
Cited by
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441703 · Cited by 588
Self-citationFluoxetine for the Treatment of Childhood Anxiety Disorders
BIRMAHER, B., AXELSON, D. A., MONK, K., KALAS, C., CLARK, D. B., EHMANN, M., BRIDGE, J., HEO, J., & BRENT, D. A. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000037049.04952.9f · Cited by 385
Relation between anxiety and depressive disorders in childhood and adolescence
Axelson, D. A., & Birmaher, B. (2001) · Depression and Anxiety · doi:10.1002/da.1048 · Cited by 365
Rynn, M. A., Siqueland, L., & Rickels, K. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2008 · Cited by 321
School Refusal in Children and Adolescents: A Review of the Past 10 Years
KING, N. J., & BERNSTEIN, G. A. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00014 · Cited by 310
Assessment and Treatment of Anxiety Disorders in Children and Adolescents
Wehry, A. M., Beesdo-Baum, K., Hennelly, M. M., Connolly, S. D., & Strawn, J. R. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0591-z · Cited by 294
Patterns of Psychiatric Comorbidity with Attention-Deficit/Hyperactivity Disorder
Pliszka, S. R. (2000) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/s1056-4993(18)30105-6 · Cited by 257
Wagner, K. D., Berard, R., Stein, M. B., Wetherhold, E., Carpenter, D. J., Perera, P., Gee, M., Davy, K., & Machin, A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1153 · Cited by 240
“This study is therefore a welcome addition to the growing evidence base for the utility of SSRIs in the treatment of anxiety disorders in children.(15,18,19) While specialized individual and group behavioral therapies have also shown benefit in the treatment of childhood social anxiety disorder,(36-40) a paucity of sk…”
BackgroundWang, Z., Whiteside, S. P. H., Sim, L., Farah, W., Morrow, A. S., Alsawas, M., Barrionuevo, P., Tello, M., Asi, N., Beuschel, B., et al. (2017) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2017.3036 · Cited by 234
SET-C Versus Fluoxetine in the Treatment of Childhood Social Phobia
BEIDEL, D. C., TURNER, S. M., SALLEE, F. R., AMMERMAN, R. T., CROSBY, L. A., & PATHAK, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318154bb57 · Cited by 223
The evidence-based pharmacotherapy of social anxiety disorder
Blanco, C., Bragdon, L. B., Schneier, F. R., & Liebowitz, M. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000119 · Cited by 99
Offidani, E., Fava, G. A., Tomba, E., & Baldessarini, R. J. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000345316 · Cited by 94
The pharmacological management of childhood anxiety disorders: a review
Reinblatt, S. P., & Riddle, M. A. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0644-4 · Cited by 67
Psychopharmacology Interventions for Pediatric Anxiety Disorders: A Research Update
Waslick, B. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.009 · Cited by 17
“After a variety of chart reviews [11,12] and openlabel trials [13–15] were published suggesting that SSRIs were potentially efficacious and safe in pediatric anxiety disorders, published RCTs have more recently emerged.”
BackgroundAdvances in Pharmacotherapy for Pediatric Anxiety Disorders
Nicotra, C. M., & Strawn, J. R. (2023) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2023.02.006 · Cited by 16
Oar, E. L., Farrell, L. J., & Ollendick, T. H. (2019) · Pediatric Anxiety Disorders · doi:10.1016/b978-0-12-813004-9.00007-4 · Cited by 7
(2017) · doi:10.23970/ahrqepccer192 · Cited by 5
The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder
Castagna, P. J., Farahdel, E., Potenza, M. N., & Crowley, M. J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2199921 · Cited by 3
Psychopharmacology for Social Anxiety Disorder
Blanco, C., Bragdon, L., Schneier, F. R., & Liebowitz, M. R. (2014) · Social Anxiety · doi:10.1016/b978-0-12-394427-6.00022-4 · Cited by 2
Metadata
- Authors
- FAIRBANKS, J. M., PINE, D. S., TANCER, N. K., DUMMIT, E. S., KENTGEN, L. M., MARTIN, J., ASCHE, B. K., & KLEIN, R. G.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 1997-01
- Volume
- 7
- Issue
- 1
- Pages
- 17-29
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2071246021
- Cited by
- 116
- References
- 1
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.